---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-056655"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:53:39.494812+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock reports Q1 net loss $105.5M; FDA accepts apitegromab BLA with Sep 30 PDUFA

## Summary
- FDA accepted apitegromab BLA for SMA; PDUFA action date Sep 30, 2026; two fill-finish facilities included.
- Cash of $479.9M as of Mar 31, 2026, includes $100M debt draw and $98M ATM proceeds.
- Q1 2026 net loss $105.5M ($0.83 per share) vs $74.7M ($0.67) in Q1 2025; no revenue.
- R&D expense $51.8M, G&A $50.2M; stock-based compensation $18.2M.
- Pipeline: Phase 2 OPAL trial enrolling; FORGE FSHD trial on track for mid-2026; SRK-439 Phase 1 data H2 2026.

## SEC filing metadata
- accession: 0001104659-26-056655
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000110465926056655/0001104659-26-056655-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000110465926056655/srrk-20260507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-056655
- JSON: https://secwatch.observer/filing/0001104659-26-056655.json
- Plain text: https://secwatch.observer/filing/0001104659-26-056655.txt

## Source-grounded claims
- claim_id: 540240800e874d42fd93f6a6ff9b7ea79663c577
  claim: Scholar Rock Holding Corp reported the quarter ended March 31, 2026 results: net income $105.5 million, EPS $0.83.
  evidence_excerpt: Scholar Rock reported a net loss of $105.5 million, including stock-based compensation of $18.2 million, for the quarter ended March 31, 2026, compared to a net loss of $74.7 million, including stock-based compensation of $13.4 million, for the quarter ended March 31, 2025. Net loss per common share was $0.83 for the quarter ended March 31, 2026, compared to $0.67 per common share for the quarter ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1727196/000110465926056655/0001104659-26-056655-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.